Cerebral toxoplasmosis after rituximab for pemphigus vulgaris

Lee, Erica B; Ayoubi, Noura; Albayram, Mehmet Sait; Kariyawasam, Vidhu; Motaparthi, Kiran

doi:10.1016/j.jdcr.2019.10.015

Cited by 10 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been approved by the European Medicines Agency for the treatment of haematological malignancies, rheumatoid arthritis, pemphigus vulgaris or granulomatosis, but it is used in several others off‐label indications, as in this case where it was used to treat dermatomyositis 3 . Cerebral toxoplasmosis has been described in other patients treated with rituximab associated with other immunosuppressive treatment 1,2 . To the best of our knowledge, no cases have been described in patients diagnosed with a dermatomyositis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cerebral toxoplasmosis associated with treatment with rituximab, azathioprine and prednisone for dermatomyositis

Castaño-Amores

Nieto-Gómez

2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

We observed a severe case of cerebral toxoplasmosis in a 22‐year‐old woman diagnosed with dermatomyositis in 2016 in Venezuela, and treated with rituximab and azathioprine. The patient met clinical and microbiological criteria. Treatment with pyrimethamine and sulfadiazine was initiated, and the patient was discharged. She was rehospitalized with signs and symptoms of a manic episode. During hospitalization, the patient developed acute kidney injury related to sulfadiazine crystalluria. Finally, acute kidney injury was resolved and the patient was successfully discharged.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Cerebral toxoplasmosis is a rare complication of immunosuppressive treatments. Only a few cases are described in the literature in patients treated with rituximab 1,2 . At present, this adverse event is not described in the product information for drugs such as rituximab or azathioprine 3,4 .…”

Section: Introductionmentioning

confidence: 99%

Cerebral toxoplasmosis associated with treatment with rituximab, azathioprine and prednisone for dermatomyositis

Castaño-Amores

Nieto-Gómez

2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…The reactivation of chronic toxoplasmosis was also reported following chemotherapy administration. Indeed, several cases of reactivation of cerebral toxoplasmosis following rituximab therapy were described [57][58][59][60]. The reactivation of toxoplasmosis is also a concern in solid organ transplant recipients, either as a manifestation derived from an infected donor, a reactivation of chronic toxoplasmosis in the recipient, or to a much lesser extent, a primary acquired infection following transplantation.…”

Section: Toxoplasmosis In Immunocompromised Patientsmentioning

confidence: 99%

Comprehensive Overview of Toxoplasma gondii-Induced and Associated Diseases

et al. 2021

View full text Add to dashboard Cite

Toxoplasma gondii (T. gondii) is a prevalent protozoan parasite of medical and veterinary significance. It is the etiologic agent of toxoplasmosis, a neglected disease in which incidence and symptoms differ between patients and regions. In immunocompetent patients, toxoplasmosis manifests as acute and chronic forms. Acute toxoplasmosis presents as mild or asymptomatic disease that evolves, under the host immune response, into a persistent chronic disease in healthy individuals. Chronic toxoplasmosis establishes as latent tissue cysts in the brain and skeletal muscles. In immunocompromised patients, chronic toxoplasmosis may reactivate, leading to a potentially life-threatening condition. Recently, the association between toxoplasmosis and various diseases has been shown. These span primary neuropathies, behavioral and psychiatric disorders, and different types of cancer. Currently, a direct pre-clinical or clinical molecular connotation between toxoplasmosis and most of its associated diseases remains poorly understood. In this review, we provide a comprehensive overview on Toxoplasma-induced and associated diseases with a focus on available knowledge of the molecular players dictating these associations. We will also abridge the existing therapeutic options of toxoplasmosis and highlight the current gaps to explore the implications of toxoplasmosis on its associated diseases to advance treatment modalities.

show abstract

“…CNS toxoplasmosis is mainly encountered in immunocompromised patients including those with human immunodeficiency virus infection or acquired immunodeficiency syndrome (HIV/AIDS), those with hematologic diseases, and those with solid-organ or bone marrow transplants. There have been only a few cases of CNS toxoplasmosis described in individuals who are on immunosuppressive agents for autoimmune diseases [9] , [10] , [11] , [12] , [13] . We therefore sought to report a case of CNS toxoplasmosis in a non-HIV immunosuppressed individual seen at our institution.…”

Section: Introductionmentioning

confidence: 99%

CNS toxoplasmosis, a rare presentation in a patient with Myasthenia Gravis

King,

Sekar,

Patel

et al. 2023

IDCases

View full text Add to dashboard Cite

Cerebral toxoplasmosis after rituximab for pemphigus vulgaris

Cited by 10 publications

References 7 publications

Cerebral toxoplasmosis associated with treatment with rituximab, azathioprine and prednisone for dermatomyositis

Cerebral toxoplasmosis associated with treatment with rituximab, azathioprine and prednisone for dermatomyositis

Comprehensive Overview of Toxoplasma gondii-Induced and Associated Diseases

CNS toxoplasmosis, a rare presentation in a patient with Myasthenia Gravis

Contact Info

Product

Resources

About